rly-4008
relay therapeutics
['rly-4008']
late breaking data presented at esmo congress 2022 demonstrate potential of rly-4008 to transform treatment options for cholangiocarcinoma patients with fgfr2-driven disease 
ARID1A, ASXL1, CDKN2C loss, GNA11, MLH1 loss,
PBRM1, TGFBR2, TP53.
STAGE 3 T3N0Mx #intrahepatic #cholangiocarcinoma NED 05/29/2020 #CholangioTwitter